New white paper outlines how FDA can increase prescription drug competition to reduce costs | PCMA press release: How FDA can increase competition among branded, generic and specialty medications | Read the white paper from PCMA
Web Version
 
November 17, 2014
FOLLOW PCMA ON TWITTER  Twitter
PCMA SmartBrief
News for the PBM Industry
SIGN UP|FORWARD|ARCHIVE

Featured Story
New white paper outlines how FDA can increase prescription drug competition to reduce costs
A new white paper authored by Alex Brill, CEO of Matrix Global Advisors, presents options policymakers can consider for lowering drug costs. The FDA should approve competing brands and generic drugs faster and should issue final guidance for developing biosimilar drugs, the PCMA paper says. Politico/Politico Pulse blog (11/17)
Share: LinkedInTwitterFacebookGoogle+Email
Legislative & Regulatory News
ACA enrollment period opens with minor snags
About 100,000 people applied for a health insurance plan through the federally run exchange on the first day of open enrollment, HHS Secretary Sylvia Mathews Burwell said. Washington state's exchange was taken offline temporarily because it was reporting incorrect tax credit data, and California officials reported unspecified problems. Hawaii, Maryland and Massachusetts reported no problems. Bloomberg (11/17), Kaiser Health News (11/17), The New York Times (tiered subscription model) (11/17)
Share: LinkedInTwitterFacebookGoogle+Email
GAO reports on small-business exchange enrollment
Close to 80,000 workers were enrolled in health insurance through 18 state-run small-business exchanges as of June 1, a Government Accountability Office report states. The figure is lower than projected, but states have worked to improve the marketplaces and boost participation. The Washington Post (tiered subscription model) (11/13), The Associated Press (11/13)
Share: LinkedInTwitterFacebookGoogle+Email
Drug Industry Spotlight
Merck KGaA and Pfizer join forces on cancer immunotherapy
Pfizer will pay Germany-based Merck KGaA $850 million upfront for rights to develop its experimental cancer immunotherapy and will pay as much as $2 billion in the future if the drug sees success. The deal restricts collaboration with other drugmakers on similar immunotherapies, dampening the prospect that Pfizer will acquire AstraZeneca, analysts say. Reuters (11/17)
Share: LinkedInTwitterFacebookGoogle+Email
SmartQuote
Failure will never overtake me if my determination to succeed is strong enough."
-- Og Mandino,
American author
Share: LinkedInTwitterFacebookGoogle+Email
About PCMA
PCMA is the national association representing America's pharmacy benefit managers (PBMs), which administer prescription drug plans for more than 216 million Americans with health coverage provided through Fortune 500 employers, health insurance plans, labor unions, and Medicare Part D. PCMA is dedicated to enhancing the proven tools and techniques pioneered by PBMs that generate savings and access for consumers and payors.

Contact PCMA
Charles Cote
Vice President, Strategic Communications
(202) 207-3610
Subscriber Tools
Please contact one of our specialists for advertising opportunities, editorial inquiries, job placements, or any other questions.
 
Editor:  Melissa Turner
 
 

Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2014 SmartBrief, Inc.®
Privacy policy |  Legal Information